☆ 4.7 Editorial Material

Lp(a) and cardiovascular disease-Has the phoenix finally risen from the ashes?

EUROPEAN HEART JOURNAL (2019)

Journal

EUROPEAN HEART JOURNAL

Volume 40, Issue 33, Pages 2771-2774

Publisher

OXFORD UNIV PRESS

DOI: 10.1093/eurheartj/ehz016

Keywords

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

A phoenix rises from the ashes of cardiac cell therapy

Eduardo Marban

Summary: The field of cardiac cell therapy has faced skepticism due to past hype, misconduct, and setbacks, but promising clinical data and deeper mechanistic understanding offer hope for its future.

NATURE REVIEWS CARDIOLOGY (2021)

Add to Collection

Article Economics

Has mortality risen disproportionately for the least educated?

Adam A. Leive, Christopher J. Ruhm

Summary: The study found that in the early 21st century, the least educated population groups tended to have the highest mortality rates, especially among men. However, there were also some groups where this pattern was reversed or the differences were not statistically significant.

JOURNAL OF HEALTH ECONOMICS (2021)

Add to Collection

Review Oncology

Therapeutic vaccines for breast cancer: Has the time finally come?

Chiara Corti, Pier P. M. B. Giachetti, Alexander M. M. Eggermont, Suzette Delaloge, Giuseppe Curigliano

Summary: The use of the immune system as a weapon against cancer, particularly through immune checkpoint inhibitors (ICIs), has revolutionized cancer treatment. However, the effectiveness of ICIs in treating breast cancer (BC) is limited, except for certain subsets of triple-negative BCs. The tumor microenvironment (TME), which is immune-suppressive in BC, plays a crucial role in the poor response to immunotherapy. Cancer vaccines (CVs), as active immunotherapy, have regained attention due to technological advancements and the COVID-19 pandemic, with a focus on neoantigens as preferred targets. Lipid nanoparticles have also shown promise as effective delivery vehicles for CVs. Past clinical trials mainly focused on metastatic disease, where the TME is more likely compromised by inhibitory mechanisms. Promising strategies include using CVs as monotherapy in premalignant or adjuvant settings, and combining CVs with ICIs in late-stage disease. This review provides a comprehensive overview of the current landscape of breast cancer vaccines.

EUROPEAN JOURNAL OF CANCER (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Lp(a) and the Risk for Cardiovascular Disease: Focus on the Lp(a) Paradox in Diabetes Mellitus

Karam M. Kostner, Gerhard M. Kostner

Summary: Lp(a) is one of the strongest causal risk factors of atherosclerotic disease, and its plasma levels are influenced by various factors. The impact of diabetes type and metabolic control on Lp(a) concentrations differs.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Article Hematology

Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease: New Insights From a Large National Biobank

Aniruddh P. Patel, Minxian Wang, James P. Pirruccello, Patrick T. Ellinor, Kenney Ng, Sekar Kathiresan, Amit V. Khera

Summary: This study suggests that there is a linear relationship between Lp(a) concentrations and ASCVD risk, with differences in concentrations across racial subgroups but similar associated risks. High Lp(a) concentrations are also associated with incident ASCVD.

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

Elevated Lp(a) and course of COVID-19: Is there a relationship?

Agnieszka Pawlos, Paulina Gorzelak-Pabis, Mateusz Staciwa, Marlena Broncel

Summary: This study explored the relationship between elevated Lp(a) levels and the severity of COVID-19 in patients. The results showed that patients with elevated Lp(a) levels had a more severe course of the disease, as evidenced by longer hospitalization time, more extensive radiological changes, and higher oxygen demand on admission. Elevated Lp(a) levels were also associated with a higher risk of High Flow Nasal Oxygen Therapy, Intubation and ICU treatment, and death.

PLOS ONE (2022)

Add to Collection

Article Environmental Studies

The advent of digital twins in surface mining: Its time has finally arrived

Arman Hazrathosseini, Ali Moradi Afrapoli

Summary: The weaknesses of conventional simulations and the increasing capabilities offered by technological trends have driven the surface mining industry towards Mining 4.0. The Digital Twin concept, with its focus on real-time data exchange and cognitive decision-making, is seen as the key to the mines of the future. This research provides a comprehensive review of simulation applications in surface mining, dissects the concept of twinning, unveils an exemplary architecture for Digital Twin in surface mines, and explores the challenges and opportunities of this disruptive technology.

RESOURCES POLICY (2023)

Add to Collection

Article Sociology

A Phoenix rising from the ashes: China's Tongqi, marriage fraud, and resistance

Eileen Y. H. Tsang

Summary: The article discusses the phenomenon of "Tongqi" in China, revealing the challenges they face and their social death situations. Tongqi not only face the risk of physical and psychological death, but also risk losing custody of their children after divorce. They should not be simply perceived as passively awaiting death, but rather as actively resisting and overcoming their circumstances.

BRITISH JOURNAL OF SOCIOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Lipid Profile, Lp(a) Levels, and HDL Quality in Adolescents with Down Syndrome

Aleksandra Krzesinska, Anna Klosowska, Kornelia Salaga-Zaleska, Agnieszka Cwiklinska, Agnieszka Mickiewicz, Gabriela Chyla, Jolanta Wierzba, Maciej Jankowski, Agnieszka Kuchta

Summary: This study aimed to evaluate lipid markers that may clarify cardiovascular risk profiles in individuals with Down syndrome (DS). The results showed that individuals with DS have an unfavorable lipid profile, higher levels of Lp(a), and changes in HDL particle quality.

JOURNAL OF CLINICAL MEDICINE (2022)

Add to Collection

Editorial Material Medicine, Research & Experimental

MicroRNAs as messengers of liver diseases: has the message finally been decrypted? Comment

Carlos J. Pirola, Silvia Sookoian

Summary: MicroRNAs (miRNAs) are crucial regulators of gene expression and cell biology, existing as stable molecules in various body fluids. Circulating miRNAs have potential applications in diagnosing liver pathologies, and some miRNAs may act in similar biological processes, making the miRNA regulatory networks more complex than expected.

CLINICAL SCIENCE (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Emerging RNA Therapeutics to Lower Blood Levels of Lp(a) JACC Focus Seminar 2/4

Sotirios Tsimikas, Patrick M. Moriarty, Erik S. Stroes

Summary: Lipoprotein(a) [Lp(a)] has been recognized as a cardiovascular disease risk factor, and new therapies are being developed to effectively reduce its levels, with ongoing clinical trials to further evaluate their effectiveness. The testing of new Lp(a)-targeted therapies will provide evidence on whether lowering Lp(a) levels can eliminate associated risks.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)

Add to Collection

Article Geochemistry & Geophysics

Has the Tibetan Plateau risen in the Early/Mid-Miocene? Constraints from plate-motion reconstructions and seismicity of the Indian Ocean lithosphere

Giampiero Iaffaldano

Summary: The onset of deformation in the Indian Ocean lithosphere in the Early/Mid-Miocene was correlated with slowdowns in plate motions. By utilizing models of viscous/brittle dynamics, the amount of force exerted by the Tibetan region on the Indian tectonic setting was constrained. Results suggest that only a minimal uplift of the Tibetan Plateau of a few hundred meters is needed to explain the contractional deformation and plate-motion slowdowns in the Indian Ocean during the Early/Mid-Miocene.

GEOPHYSICAL JOURNAL INTERNATIONAL (2021)

Add to Collection

Article Nutrition & Dietetics

Genetically Higher Level of Mannose Has No Impact on Cardiometabolic Risk Factors: Insight from Mendelian Randomization

Mohsen Mazidi, Abbas Dehghan, Maciej Banach

Summary: The study concluded that mannose has no significant effect on coronary artery disease (CAD) and other cardiometabolic risk factors. There were no significant differences or outliers found in the various indicators examined.

NUTRIENTS (2021)

Add to Collection

Article Materials Science, Multidisciplinary

Rising Like a Phoenix from the Ashes: Fire-Proof Magnetically Retrievable Supraparticles with an Optical Fingerprint for Postmortem Identification of Products

Franziska Miller, Sarah Wenderoth, Susanne Wintzheimer, Karl Mandel

Summary: This study presents fire-proof postmortem taggants called optomagnetic supraparticles (SPs), which are composed of luminescent and magnetic nanoparticles (NPs). These taggants can be used to differentiate between genuine and counterfeit products even after a fire incident, using ratiometric luminescence signals. The research successfully achieves the desired functionality of the fire-proof taggants by carefully choosing the type and ratios of nanoparticles and process parameters.

ADVANCED OPTICAL MATERIALS (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Prevalence and influence of LPA gene variants and isoform size on the Lp (a)-lowering effect of pelacarsen

Ewa Karwatowska-Prokopczuk, Noemie Clouet-Foraison, Shuting Xia, Nicholas J. Viney, Joseph L. Witztum, Santica M. Marcovina, Sotirios Tsimikas

Summary: This study analyzed data from 4 clinical trials of the ASO pelacarsen targeting apolipoprotein(a) in 455 patients, finding that LPA genetic variants do not affect the efficacy of pelacarsen.

ATHEROSCLEROSIS (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Implications of ACC/AHA Versus ESC/EAS LDL-C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study From DA VINCI

Antonio J. Vallejo-Vaz, Sarah Bray, Guillermo Villa, Julia Brandts, Gaia Kiru, Jennifer Murphy, Maciej Banach, Stefano De Servi, Dan Gaita, Ioanna Gouni-Berthold, G. Kees Hovingh, Jacek J. Jozwiak, J. Wouter Jukema, Robert Gabor Kiss, Serge Kownator, Helle K. Iversen, Vincent Maher, Luis Masana, Alexander Parkhomenko, Andre Peeters, Piers Clifford, Katarina Raslova, Peter Siostrzonek, Stefano Romeo, Dimitrios Tousoulis, Charalambos Vlachopoulos, Michal Vrablik, Alberico L. Catapano, Neil R. Poulter, Kausik K. Ray

Summary: In patients with atherosclerotic cardiovascular disease (ASCVD), achieving European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) LDL-C goals may result in an additional 2% absolute risk reduction (ARR) over 10 years compared to the American College of Cardiology/American Heart Association (ACC/AHA) approach.

CARDIOVASCULAR DRUGS AND THERAPY (2023)

Add to Collection

Article Medicine, General & Internal

The DA VINCI study: is Ireland achieving ESC/EAS guideline-directed LDL-C goals?

Gregory Offiah, Cormac O'Connor, Cormac Kennedy, Joe Gallagher, Patricia O'Connor, Brendan McAdam, Kausik K. Ray, Marieke Schoonen, Vincent Maher

Summary: The DA VINCI study assessed LDL-C goal attainment in patients in Ireland and found a disparity between dyslipidaemia management in clinical practice and guideline recommendations.

IRISH JOURNAL OF MEDICAL SCIENCE (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Potential Cardiovascular Events Avoided with Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared with Ezetimibe Alone in Patients with Atherosclerotic Cardiovascular Disease Taking Maximally Tolerated Statins

R. Brett McQueen, Seth J. Baum, Michael J. Louie, William J. Sasiela, Aikaterini Bilitou, Hemal Shah, Beth Nash, Kristin K. Gillard, Kausik K. Ray

Summary: This study found that adding bempedoic acid plus ezetimibe to maximally tolerated statins can further reduce LDL-C and decrease the risk of major adverse cardiovascular events in patients with atherosclerotic cardiovascular disease. The benefits may be greater for patients with higher baseline LDL-C levels.

AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Long-term persistence with evolocumab treatment and sustained reductions in LDL-cholesterol levels over 30 months: Final results from the European observational HEYMANS study

Kausik K. Ray, Eric Bruckert, Pasquale Peronne-Filardi, Christoph Ebenbichler, Anja Vogt, Ian Bridges, Mahendra Sibartie, Nafeesa Dhalwani

Summary: This study aimed to evaluate the long-term persistence and LDL-C level reductions of evolocumab in routine clinical practice using data from the HEY-MANS registry. The results showed that evolocumab therapy was associated with sustained LDL-C level reductions up to 30 months, and patients had high persistence with evolocumab even at 12 and 30 months of follow-up.

ATHEROSCLEROSIS (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Inclisiran and cardiovascular events: a patient-level analysis of phase III trials

Kausik K. Ray, Frederick J. Raal, David G. Kallend, Mark J. Jaros, Wolfgang Koenig, Lawrence A. Leiter, Ulf Landmesser, Gregory G. Schwartz, David Lawrence, Andrew Friedman, Lorena Garcia Conde, R. Scott Wright

Summary: Exploratory findings from the ORION trials suggest that treatment with inclisiran is associated with reductions in major cardiovascular events, providing potential cardiovascular benefits.

EUROPEAN HEART JOURNAL (2023)

Add to Collection

Article Pharmacology & Pharmacy

Effects of bempedoic acid on CRP, IL-6, fibrinogen and lipoprotein(a) in patients with residual inflammatory risk: A secondary analysis of the CLEAR harmony trial

Paul M. Ridker, Lei Lei, Kausik K. Ray, Christie M. Ballantyne, Gary Bradwin, Nader Rifai

Summary: Bempedoic acid (BA) reduces hsCRP and LDL-C levels in patients with atherosclerotic disease and/or familial hypercholesterolemia. It also shows potential anti-inflammatory effects and has similar lipid-lowering and inflammation-inhibiting properties to statin therapy.

JOURNAL OF CLINICAL LIPIDOLOGY (2023)

Add to Collection

Review Cardiac & Cardiovascular Systems

Novel and future lipid-modulating therapies for the prevention of cardiovascular disease

Julia Brandts, Kausik K. Ray

Summary: In this review, the authors discuss current and upcoming treatment strategies for lowering LDL cholesterol levels and reducing the risk of cardiovascular disease. They highlight the importance of targeting key proteins involved in lipoprotein metabolism as potential therapeutic targets. Novel approaches such as protein inhibition, mRNA level interference, and base editing are explored. The authors also address the challenge of achieving safe and long-lasting reductions in causal exposures. Overall, this review provides valuable insights into the opportunities and challenges in the field of cardiovascular disease prevention.

NATURE REVIEWS CARDIOLOGY (2023)

Add to Collection

Article Medicine, General & Internal

Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients

S. E. E. Nissen, A. M. Lincoff, D. Brennan, K. K. K. Ray, D. Mason, J. J. P. Kastelein, P. D. D. Thompson, P. Libby, L. Cho, J. Plutzky, H. E. E. Bays, P. M. M. Moriarty, V Menon, D. E. E. Grobbee, M. J. J. Louie, C-F Chen, N. Li, L. A. Bloedon, P. Robinson, M. Horner, W. J. J. Sasiela, J. McCluskey, D. Davey, P. Fajardo-Campos, P. Petrovic, J. Fedacko, W. Zmuda, Y. Lukyanov, S. J. J. Nicholls

Summary: This study demonstrates that the ATP citrate lyase inhibitor Bempedoic acid can significantly reduce low-density lipoprotein cholesterol levels and is associated with a low incidence of muscle-related adverse events. Among patients unable or unwilling to take statins, Bempedoic acid treatment significantly reduces the risk of major adverse cardiovascular events.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Add to Collection

Article Health Care Sciences & Services

Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study

Kausik K. Ray, Inaam Haq, Aikaterini Bilitou, Marius C. Manu, Annie Burden, Carlos Aguiar, Marcello Arca, Derek L. Connolly, Mats Eriksson, Jean Ferrieres, Ulrich Laufs, Jose M. Mostaza, David Nanchen, Ernst Rietzschel, Timo Strandberg, Hermann Toplak, Frank L. J. Visseren, Alberico L. Catapano

Summary: The SANTORINI study found that in Europe between 2020 and 2021, statin monotherapy was the main approach to lipid management for high-risk and very high-risk cardiovascular patients, with only one-fifth achieving the recommended LDL-C goals. The study results raised questions about whether there have been changes in the treatment landscape or if gaps still exist.

LANCET REGIONAL HEALTH-EUROPE (2023)

Add to Collection

Review Cardiac & Cardiovascular Systems

Non-HDL-cholesterol in dyslipidemia: Review of the state-of-the-art literature and outlook

Vikrama Raja, Carlos Aguiar, Nasreen Alsayed, Yogeyaa S. Chibber, Hussein Elbadawi, Marat Ezhov, Michel P. Hermans, Ramesh Chandra Pandey, Kausik K. Ray, Lale Tokgozoglu, Alberto Zambon, Jean-Pascal Berrou, Michel Farnier

Summary: Non-HDL-C has gained attention as a reliable alternative goal for dyslipidemia management, encompassing several atherogenic constituents in addition to LDL. It is considered an independent predictor for cardiovascular diseases and has shown long-term predictive ability for adverse events.

ATHEROSCLEROSIS (2023)

Add to Collection

Editorial Material Cardiac & Cardiovascular Systems

The global diagnostic network: what can we learn from half a billion lipid measurements between 2018 and 2020?

Fotios Barkas, Kausik K. Ray

EUROPEAN HEART JOURNAL (2023)

Add to Collection

Editorial Material Cardiac & Cardiovascular Systems

What about glucagon-like peptide-1 receptor agonist for all? Recent data and perspectives

Pierre Sabouret, Fiona Ecarnot, Salvatore De Rosa, Kausik K. Ray

EUROPEAN HEART JOURNAL (2023)

Add to Collection

Letter Cardiac & Cardiovascular Systems

Evolocumab use in Greece is associated with early and sustainable reductions in low-density cholesterol (LDL-C) and high persistence to therapy: Results from the Greek cohort analysis of the observational HEYMANS study

C. Vlachopoulos, D. Massia, G. Kochiadakis, G. Kolovou, S. Patsilinakos, I. Bridges, M. Sibartie, N. N. Dhalwani, E. Liberopoulos, K. K. Ray

HELLENIC JOURNAL OF CARDIOLOGY (2023)

Add to Collection

Article Medicine, General & Internal

Evolocumab effectiveness in the real-world setting: Austrian data from the pan-European observational HEYMANS study

Christoph Ebenbichler, Heinz Drexel, Ursula Hanusch, Hermann Toplak, Nafeesa N. Dhalwani, Ian Bridges, Robert Hoelzl, Margit Hemetsberger, Kausik K. Ray

Summary: A study conducted in Austria showed that patients initiating evolocumab had high persistence and significant reduction in LDL-C levels, leading to decreased cardiovascular risk.

WIENER KLINISCHE WOCHENSCHRIFT (2023)

Add to Collection

Article Peripheral Vascular Disease

Lipoprotein(a), Interleukin-6 inhibitors, and atherosclerotic cardiovascular disease: Is there an association?

Anastasios Makris, Fotios Barkas, Petros P. Sfikakis, Evangelos Liberopoulos, Theodosios D. Filippatos, Kausik K. Ray, Aris P. Agouridis

Summary: This study investigated the association between lipoprotein(a) [Lp(a)] and interleukin-6 (IL-6) and their potential clinical implications in preventing atherosclerotic cardiovascular disease (ASCVD). The findings suggest that elevated Lp(a) levels are associated with ASCVD and IL-6(R)i can lower Lp(a) levels and potentially have anti-atherosclerotic effects.

ATHEROSCLEROSIS PLUS (2023)

Add to Collection

No Data Available

Lp(a) and cardiovascular disease-Has the phoenix finally risen from the ashes?

Journal

Publisher

OXFORD UNIV PRESS

Keywords

Categories

Ask authors/readers for more resources

Protocol

Reagent

Authors

I am an author on this paper

Reviews

Primary Rating

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Recommended

Export Citation

Share Paper